share_log

Verve Therapeutics Analyst Ratings

Verve Therapeutics Analyst Ratings

神韻治療分析師評級
Benzinga Analyst Ratings ·  2023/02/01 07:57
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
02/01/2023 -7.69% Cantor Fitzgerald → $21 Initiates Coverage On → Neutral
12/15/2022 -42.86% Goldman Sachs → $13 Initiates Coverage On → Sell
11/08/2022 53.85% RBC Capital $42 → $35 Maintains Outperform
10/06/2022 110.99% Credit Suisse → $48 Initiates Coverage On → Neutral
08/25/2022 146.15% Stifel $32 → $56 Upgrades Hold → Buy
07/18/2022 172.53% BMO Capital $48 → $62 Maintains Outperform
06/17/2022 110.99% BMO Capital → $48 Initiates Coverage On → Outperform
02/18/2022 84.62% RBC Capital → $42 Initiates Coverage On → Outperform
09/24/2021 154.95% Stifel → $58 Initiates Coverage On → Hold
07/12/2021 304.4% William Blair → $92 Initiates Coverage On → Outperform
07/12/2021 269.23% Guggenheim → $84 Initiates Coverage On → Buy
07/12/2021 119.78% JP Morgan → $50 Initiates Coverage On → Neutral
07/12/2021 — Jefferies Initiates Coverage On → Buy
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
02/01/2023 -7.69% 康託·菲茨傑拉德 →$21 開始承保 →中性
2022年12月15日 -42.86% 高盛 →$13 開始承保 →銷售
11/08/2022 53.85% 加拿大皇家銀行資本 $42→$35 維護 跑贏大盤
10/06/2022 110.99% 瑞士信貸 →$48 開始承保 →中性
2022年08月25日 146.15% Stifel $32→$56 升級 持有→購買
07/18/2022 172.53% 蒙特利爾銀行資本 $48→$62 維護 跑贏大盤
06/17/2022 110.99% 蒙特利爾銀行資本 →$48 開始承保 →跑贏大盤
02/18/2022 84.62% 加拿大皇家銀行資本 →$42 開始承保 →跑贏大盤
09/24/2021 154.95% Stifel →$58 開始承保 →保留
07/12/2021 304.4% 威廉·布萊爾 →$92 開始承保 →跑贏大盤
07/12/2021 269.23% 古根海姆 →$84 開始承保 →購買
07/12/2021 119.78% 摩根大通 →$50 開始承保 →中性
07/12/2021 - 傑富瑞 開始承保 →購買

What is the target price for Verve Therapeutics (VERV)?

Verve Treateutics(VERV)的目標價格是多少？

The latest price target for Verve Therapeutics (NASDAQ: VERV) was reported by Cantor Fitzgerald on February 1, 2023. The analyst firm set a price target for $21.00 expecting VERV to fall to within 12 months (a possible -7.69% downside). 8 analyst firms have reported ratings in the last year.

康託·菲茨傑拉德於2023年2月1日報道了Verve治療公司(納斯達克代碼：VERV)的最新目標價。這家分析公司將目標價定為21.00美元，預計VERV將在12個月內降至(可能下跌7.69%)。去年有8家分析公司公佈了評級。

What is the most recent analyst rating for Verve Therapeutics (VERV)?

Verve Treateutics(VERV)的最新分析師評級是什麼？

The latest analyst rating for Verve Therapeutics (NASDAQ: VERV) was provided by Cantor Fitzgerald, and Verve Therapeutics initiated their neutral rating.

對Verve治療公司(納斯達克代碼：VERV)的最新分析師評級是由坎託·菲茨傑拉德提供的，Verve治療公司啟動了他們的中性評級。

When is the next analyst rating going to be posted or updated for Verve Therapeutics (VERV)?

Verve治療公司(VERV)的下一次分析師評級將於何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verve Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verve Therapeutics was filed on February 1, 2023 so you should expect the next rating to be made available sometime around February 1, 2024.

分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Verve Treeutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Verve治療公司的上一次評級是在2023年2月1日提交的，所以你應該預計下一次評級將在2024年2月1日左右的某個時候提供。

Is the Analyst Rating Verve Therapeutics (VERV) correct?

分析師對Verve Treateutics(VERV)的評級正確嗎？

While ratings are subjective and will change, the latest Verve Therapeutics (VERV) rating was a initiated with a price target of $0.00 to $21.00. The current price Verve Therapeutics (VERV) is trading at is $22.75, which is out of the analyst's predicted range.

雖然評級是主觀的，並將發生變化，但最新的Verve Treateutics(VERV)評級是以0.00美元至21.00美元的目標價啟動的。Verve Treateutics(VERV)目前的交易價格為22.75美元，超出了分析師的預測範圍。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論